Hunt told in-PharmaTechnologist that the 13,000 sq ft primary and secondary trial packaging unit, which expands the active pharmaceutical ingredient (API), formulations and packing site in Morpeth, is part of an effort to offer a “one stop shop” for the drug industry.
He said that: “clinical trials are a very important revenue stream for Piramal,” and added that the expansion enables the firm to offer customers everything from API development to trial scale manufacture and ultimately commercial scale production.
New CTS website
Ian Morgan, head of Piramal’s clinical trial services (CTS), also told in-PharmaTechnologist about the potential benefits of the integrated formulations and clinical trial packaging offering.
He explained that the trial centre can conduct primary and secondary packaging for both solid and liquid products, which are then labelled according to trial protocols before being securely shipped to global trial sites worldwide via the dedicated distribution centre.
Piramal also launched a new website to both publicise its CTS offering and allow existing customers to monitor the status of their projects using the firm’s in-house “TrakPack” monitoring system.
Morgan said that: “This interactive website is vital in the evolution of our business and will help our customers better understand our offering.”
Piramal has been building its clinical offering for the last few years, most notably with the acquisition of Tangent Data, a Romanian contract research organisation (CRO) specialising in the central nervous system (CNS) in 2008.
Commenting at the time of the Tangent deal, Piramal said that it is planning on expanding further over the next three years, setting up operations in Western and Eastern Europe, South Asia and North America.